Healthy revenue growth in Q1 25

Encompass Health Corporation reported a 10.6% y/y increase in net operating revenues for Q1 2025, reaching $1,455.4m, driven by higher patient volumes and favorable pricing. Total discharges rose by 6.3% to 64,985, including a 4.4% increase in same-store discharges. Growth in discharges from new stores was supported by new facilities in various locations, including joint ventures and wholly owned hospitals. Net patient revenue per discharge grew by 3.9% y/y to $21,816 due to increased reimbursement rates.

Adjusted EBITDA moved up by 14.9% y/y to $313.6m, with margins improving by 80 bp to 21.5%, attributed to lower expenses as a percentage of sales from higher volumes. Net income surged by 34.7% y/y to $151.5m, driven by higher revenue, which also trickled down to a 20.9% growth in CFO, totaling $288.6m.

In 2025, the company achieved several milestones in development and expansion. It began operating a new 40-bed inpatient rehabilitation hospital in Athens, Georgia, in partnership with Piedmont, added 25 new beds to existing hospitals, and announced further hospital developments.

Aging population driving demand

The company remains optimistic about its intermediate and long-term business prospects. It operates in a large, underpenetrated, and expanding inpatient rehabilitation market, characterized by a low conversion rate of presumptively eligible patients. The fragmented nature of the sector offers numerous opportunities for unit acquisition and joint ventures. The company also benefits from significant barriers to entry and economies of scale.

It has a resilient business model centered around non-discretionary conditions predominantly affecting an aging population. Furthermore, it expects the demand for rehabilitation services to rise owing to favorable demographics. The majority of its patients are aged 65+, with Medicare enrollees projected to grow by 3% p.a., reaching 73m by 2030. The average age of its Medicare patients is 78, and the population aged 75 to 79 is expected to grow by 5% annually through 2026.

Upward revision in guidance

Encompass Health Corporation has updated its FY 25 guidance, showing growth in net operating revenue from $5,800-$5,900m to $5,850-$5,925m and adjusted EBITDA from $1,160-$1,200m to $1,185-$1,220m. Adjusted EPS forecast from continuing operations has improved from $4.67-$4.96 to $4.85-$5.10. Medicare pricing will increase by 3.3% for Q2 and Q3 and an estimated 2.7% for Q4, with managed care pricing rising by 2.0%-3.0%. Capacity expansions include seven new hospitals with 340 beds, a 50-bed satellite hospital, and 100-120 additional beds to existing hospitals, with pre-opening and ramp-up costs estimated at $18-$22m.

Encompass Health's 2023-2027 growth targets include 6 to 10 de novo hospitals per year, 80 to 120 bed additions per year, and a 6% to 8% discharge CAGR. It has also announced its preliminary plans include building a 50-bed inpatient rehabilitation hospital in Apollo Beach, Florida, expected to open in 2027, and another in North Las Vegas, Nevada, expected to open by 2028.

Recovery in margins

Encompass Health Corporation achieved a revenue CAGR of 10.2% from FY 21 to FY 24, reaching $5.4bn in FY 24. Operating income grew by 9.4% to $864.5m, with operating margins recovering to 16.1% in FY 24. Cash flows from operations grew at a CAGR of 11.9%, reaching $1.0bn in FY 24.

Analysts project a revenue CAGR of 8.6% from FY 24 to FY 27, reaching $6.9bn. Operating income is expected to grow at a CAGR of 5.6%, reaching $1.0bn with a 14.8% operating margin in FY 27. Net profit is projected to rise by a CAGR of 11.7%, reaching $635.6m with a 9.2% net profit margin in FY 27.

The Ensign Group, a local peer, achieved a 3-year revenue CAGR of 17.5%, reaching $4.3bn in FY 24. Its operating profit grew at a CAGR of 11.2% to $358.3m, with an operating margin of 8.4% in FY 24.

Stock rallied sharply

Encompass Health Corporation's stock rose sharply by 40.2% over the past year, outperforming its local peer, The Ensign Group, which increased by 26.2%. Encompass Health is currently trading at a P/E of 23.7x, lower than The Ensign Group's 26.1x but higher than its 3-year historical average of 20.7x. Its EV/EBITDA is 11.9x, below The Ensign Group's 15x but above its historical average of 10.3x.

The stock is liked by all 13 analysts covering the stock with 11 having ‘Buy ratings’ and 2 having ‘Outperform’ ratings. They have set an average target price of $131.6, implying 10.4% upside potential from the current price. Overall, Encompass Health has demonstrated positive revenue growth and improved cash flows. It benefits from a growing inpatient rehabilitation market, favorable demographic trends, significant barriers to entry, economies of scale, and a resilient business model. The stock has achieved significant returns, with bullish sentiment reflected in analyst ratings growth forecasts. However, risks include operating in a highly regulated industry, staffing shortages and increased labor costs, and potential reductions or delays in reimbursement from government and private payors, which could adversely affect financial results.

https://www.marketscreener.com/quote/stock/ENCOMPASS-HEALTH-CORPORAT-39742680/news/Growth-trajectory-remains-robust-for-Encompass-Health-50316186/